Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2019 Oct 12;21(Suppl 4):iv17. doi: 10.1093/neuonc/noz167.073

Management and outcomes of meningiomas secondary to childhood and adolescent radiation treatment

Conor Gillespie 1,2, Abdurrahman Islim 1,2, Siddhant Kumar 1,2, Nitika Rathi 2, Catherine Gilkes 2, Emmanuel Chavredakis 2, David Lawson 2, Samantha Mills 2, Andrew Brodbelt 2, Michael Jenkinson 1,2
PMCID: PMC6789692

Abstract

Background

With the increased rate of childhood cancer survivors, a marked rise in the incidence of secondary intracranial meningiomas has been established.

Objective

Determine the outcomes of patients diagnosed with radiation-induced meningiomas (RIM).

Methods

Single-centre retrospective cohort study of patients with new or recurrent RIM (2007–2018).

Results

47 patients were identified (21 females). Mean age at radiation was 15 years (SD=14) and the most common indications were leukaemia (n=8) and childhood brain tumours (n=35; medulloblastoma and pilocytic astrocytoma (n=7 each)). 93 de-novo meningiomas were identified. The median latency period between radiation and diagnosis was 28.5 years (IQR 22–37). 61% were asymptomatic whilst the remainder manifested headache (20%), focal neurological deficit (12%) and epilepsy (5%). 32 operated de-novo RIM revealed WHO grade I (n=19; 59%), WHO grade II (n=11; 34%) and 2 intraosseous meningiomas (n=2; 6%). After a median of 5 years (IQR 3–10), 9 (28%) operated RIM recurred/progressed. At recurrence, 5 were operated (3 WHO grade I, 2 WHO grade II and 1 WHO grade III), 2 patients were palliated and 2 remain under active observation. By the end of the study period, 20 patients were harbouring multiple meningiomas and 8 patients were deceased.

Conclusion

Radiation-induced meningioma should be monitored until symptomatic. Operated RIMs have a high recurrence rate. Further radiotherapy is not effective. Further clinical and genetic analyses as part of an international multi-centre collaboration are planned.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES